Advertisement
Advertisement

Read Now: TheBodyPRO.com Covers AIDS 2014

Differences Between HIV-Infected Men and Women in Antiretroviral Therapy Outcomes -- Six African Countries, 2004-2012

November 29, 2013

 < Prev  |  1  |  2  |  3  |  4  |  5  |  6  |  Next > 

TABLE 2. (Continued) Enrollment Characteristics of Adults (N = 13,175) Initiating Antiretroviral Therapy (ART) -- Six African Countries, 2004-2010

Characteristic

Zambia
(N = 1,457)

Uganda
(N = 1,472)

Tanzania
(N = 1,458)

No.

Median
age

p-value

No.

Median
age

p-value

No.

Median
age

p-value

Sex, no., and median age

         

Women

880

34

<0.001

964

34

<0.001

973

35

<0.001

Men

575

37

 

502

37

 

484

39

 
 

No.

Median
CD4

p-value

No.

Median
CD4

p-value

No.

Median
CD4

p-value

Sex, no., and median CD4 count at ART initiation (cells/µL)

 

 

 

 

 

 

 

 

 

Women

639

139

0.261

774

144

0.012

742

137

0.232

Men

411

127

 

395

128

 

379

121

 

Missing data

407

--

 

303

--

 

337

--

 
 

No.

(%)

p-value

No.

(%)

p-value

No.

(%)

p-value

Sex, no., and %

 

 

 

 

 

 

 

 

 

Women

882

(61)

 

968

(66)

 

974

(67)

 

Men

575

(39)

 

504

(34)

 

484

(33)

 

WHO HIV disease stage

 

 

 

 

 

 

 

 

 

Stage I/II

         

Women

326

(41)

0.029

434

(51)

0.006

225

(29)

0.006

Men

170

(34)

 

205

(45)

 

76

(20)

 

Stage III

  

 

      

Women

390

(49)

 

330

(39)

 

347

(44)

 

Men

277

(55)

 

178

(39)

 

192

(50)

 

Stage IV

  

 

      

Women

73

(9)

 

87

(10)

 

212

(27)

 

Men

54

(11)

 

73

(16)

 

113

(30)

 

Missing data

167

(11)

 

165

(11)

 

293

(20)

 

Female regimens

 

 

 

 

 

 

 

 

 

NVP-3TC-D4T/AZT/TDF

606

(69)

<0.001

772

(80)

0.013

760

(78)

0.088

EFV-3TC-D4T/AZT/TDF

260

(29)

 

179

(18)

 

201

(21)

 

Triple NRTI

0

--

 

3

(<1)

 

0

--

 

PI-based

6

(1)

 

8

(1)

 

0

--

 

Unknown

0

--

 

0

--

 

0

--

 

Other

10

(1)

 

6

(1)

 

13

(1)

 

Male regimens

 

 

 

 

 

 

 

 

 

NVP-3TC-D4T/AZT/TDF

334

(58)

 

362

(72)

 

357

(74)

 

EFV-3TC-D4T/AZT/TDF

225

(39)

 

133

(26)

 

122

(25)

 

Triple NRTI

0

--

 

1

(<1)

 

0

--

 

PI-based

9

(2)

 

5

(1)

 

1

(<1)

 

Unknown

0

--

 

0

--

 

0

--

 

Other

7

(1)

 

3

(<1)

 

974

(1)

 

Abbreviations: WHO = World Health Organization; NVP = nevirapine; EFV = efavirenz; 3TC = lamivudine; D4T = stavudine; AZT = zidovudine; TDF = tenofovir; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor.

* Data for Côte d'Ivoire, Swaziland, and Mozambique are weighted to account for the sampling method.

† Data were missing for two enrollees in Zambia, six in Uganda, and one in Tanzania.

§ p-value for comparison of ART enrollee characteristics for men and women (t-test for continuous variables and chi-square test for categorical variables).

 < Prev  |  1  |  2  |  3  |  4  |  5  |  6  |  Next > 



This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication Morbidity and Mortality Weekly Report. Visit the CDC's website to find out more about their activities, publications and services.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement